The Readout Loud

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Denne podkasten er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(417)

215: Medical privacy post-Roe, fixing clinical trials, & the next Covid vaccines

215: Medical privacy post-Roe, fixing clinical trials, & the next Covid vaccines

How do you stop a Covid surge? Why are clinical trials so white? And what are the limits of HIPAA? Our colleague Eric Boodman joins us to discuss whether an oft-cited federal law can shield reproducti...

30 Jun 202234min

214: Juul's doomsday, Merck's buyout plans, & the next Theranos verdict

214: Juul's doomsday, Merck's buyout plans, & the next Theranos verdict

Just how powerful is the FDA? Is Merck about to spend $40 billion? And what's a "Puff Bar"? STAT Washington correspondent Nicholas Florko joins us to discuss the FDA's decision to ban the sale of Juul...

23 Jun 202227min

213: How the Fed affects biotech, Paul Offit on vaccines for kids, & another Alzheimer's setback

213: How the Fed affects biotech, Paul Offit on vaccines for kids, & another Alzheimer's setback

Will biotech stocks ever recover? How well do Covid-19 vaccines work for kids? And can anything stop the amyloid hypothesis? Longtime biotech investor Les Funtleyder joins us to explain why the recent...

16 Jun 202235min

212: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy

212: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy

When is data "practice-changing"? How many Covid-19 vaccines do we need? And what does it mean when the FDA asks for more time? With the world's largest cancer conference just concluded, we explain th...

9 Jun 202235min

211: Biotech's catch-22, a $100 genome, & dealing with monkeypox

211: Biotech's catch-22, a $100 genome, & dealing with monkeypox

Will gene therapy ever live up to expectations? Can anyone break up the genomics monopoly? And is innovation actually bad for biotech? This week, health care strategist Jared Holz of Oppenheimer joins...

2 Jun 202233min

210: Covid vaccines for the youngest kids, ASCO preview, & a biotech CEO’s arrest on murder charges

210: Covid vaccines for the youngest kids, ASCO preview, & a biotech CEO’s arrest on murder charges

ovid vaccines for the youngest kids are up for review, but which jab — Moderna or Pfizer — will parents choose? What’s on tap for ASCO, the biggest cancer research conference of the year? And a biotec...

26 Mai 202234min

Episode 209: Mysterious infections, dwindling Covid funds, & Shkreli out of prison

Episode 209: Mysterious infections, dwindling Covid funds, & Shkreli out of prison

What happens when the White House runs out of Covid-19 money? Why are kids suddenly getting mysterious infections? And who's going to hire Martin Shkreli? First, STAT's Helen Branswell joins us to exp...

19 Mai 202233min

Episode 208: A CEO's arrest, Pfizer's big deal, & Covid on the rise

Episode 208: A CEO's arrest, Pfizer's big deal, & Covid on the rise

Is the next Covid surge upon us? How do you make $350,000 a day in biotech? And when did Seagen find out about its CEO's arrest? First, we discuss the latest alarming trends in the Covid-19 pandemic a...

12 Mai 202232min

Populært innen Business og økonomi

stopp-verden
dine-penger-pengeradet
e24-podden
lydartikler-fra-aftenposten
rss-borsmorgen-okonominyhetene
rss-penger-polser-og-politikk
rss-skravla-gar
rss-pa-konto
pengepodden-2
utbytte
rss-orjasater
finansredaksjonen
livet-pa-veien-med-jan-erik-larssen
tid-er-penger-en-podcast-med-peter-warren
stormkast-med-valebrokk-stordalen
lederpodden
morgenkaffen-med-finansavisen
pengesnakk
rss-markedspuls-2
liberal-halvtime